News Announcement

Zydus Lifesciences: Announcement under Regulation 30 (LODR)-Press Release / Media Release

Zydus receives final approvals from USFDA for Ivermectin Tablets USP 3 mg and Dapsone Tablets USP 25 mg and 100 mg.

Disclaimer: This content is for information only and should not be considered investment advice or a recommendation.

Ask Value Research aks value research information

No question is too small. Share your queries on personal finance, mutual funds, or stocks and let us simplify things for you.